ArticleClinical and experimental medicine2017
Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations.
Article in Clinical and experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CMV infection in active systemic lupus erythematosus: clinical characteristics, prognosis and treatment outcomes.BMC rheumatology · 2025Article
- Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function.Lupus science & medicine · 2022Article
- Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies.Lupus science & medicine · 2021Article
- Slit2 is a potential biomarker for renal impairment in systemic lupus erythematosus.Clinical and experimental medicine · 2021Article
- Evaluation of systemic lupus erythematosus disease activity using anti-α-enolase antibody and RDW.Clinical and experimental medicine · 2021Article
- Hematological abnormalities resistant to therapy in a child with systemic lupus erythematosus: Answers.Pediatric nephrology (Berlin, Germany) · 2020Article
- Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study.Rheumatology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To better clarify the clinical features and therapeutic strategy of CMV infection in lupus nephritis patients, we retrospectively surveyed a total of 40 lupus nephritis patients, who had been hospitalized and underwent renal biopsy and diagnosed as having CMV infection during their hospitalization at our institution within the last 10 years. The percentage of CMV infections in the entire hospitalized lupus nephritis population was 5.3% (40/755). The principal clinical features of the 40 CMV-infected patients were hematological disorders (n = 25), fever (n = 21), liver dysfunction (n = 19), and respiratory symptoms (n = 12). Active SLE (SLEDAI 16 ± 5), hypertriglyceridemia (3.16 ± 2.57 mmol/L), and a history of potent immunosuppressive therapy were commonly observed in this patient group. There were no significant differences of SLEDAI (P = 0.290), proteinuria (P = 0.065), hematuria (P = 0.497), CL
Indexed as
Identifiers
28213738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.